Our Journey to Innovative Bioengineering Solutions
At Nanomedsyn, we believe in the power of innovative bioengineering to change lives. Our journey began with a vision to enhance drug delivery using AMFA glycovectors, which target the mannose 6-phosphate receptor (M6PR). By grafting these glycovectors onto therapeutic antibodies, enzymes, or nanoparticles, we enable effective cellular internalization and precise routing to lysosomes. Our team is dedicated to partnering with you to develop first-in-class drugs, ensuring your research leads to groundbreaking therapies that make a real difference. Together, letʼs shape the future of medicine!
We are advancing AMFA glycovectors, a next‑generation targeting technology engineered to unlock precise cellular uptake and lysosomal delivery. Built on a flexible and modular design, our platform empowers the development of breakthrough therapeutics across multiple domains, enabling researchers to reach targets once considered out of reach.
Therapeutic Antibodies & Targeted Protein Degradation
Therapeutic antibodies are evolving with Targeted Protein Degradation (TPD), enabling the removal—not only inhibition—of disease‑driving proteins. Our technologies help reach previously undruggable targets with precision.
Enzyme Replacement Therapy (ERT)
Enhanced ERT solutions improve lysosomal targeting and tissue uptake for rare disorders like Pompe disease. Our engineered systems support more effective and long-lasting therapeutic responses.
Nanoparticles for Precision Delivery
Advanced nanoparticle systems enable precise delivery of RNA, enzymes, and biologics into difficult tissues, unlocking new possibilities for treating complex and undruggable diseases.